Amneal Pharmaceuticals (AMRX) Stock: Buy, Sell, or Hold?
AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock
$20.15
0.08 (0.40%)
▲
5d:
+1.92%
30d:
+11.57%
90d:
+19.09%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 29, 2026
26d
Get Alerted When AMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AMRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AMRX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$26.12
Based on 10.3% avg growth
INTRINSIC VALUE TODAY
$16.22
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRX is currently trading at $20.15, which is considered extended relative to its 30-day fair value range of $17.23 to $19.63. From a valuation perspective, the stock is trading at a premium (Forward PE: 16.8) compared to its historical average (13.5). At these levels, the market is pricing in 7.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AMRX is in a strong uptrend. Immediate support is located at $18.73, while resistance sits at $21.18.
Market Sentiment: AMRX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.71 (+13.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AMRX is in a strong uptrend. Immediate support is located at $18.73, while resistance sits at $21.18.
Market Sentiment: AMRX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.71 (+13.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$17.23 -
$19.63
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.2%
Protect Your Profits
Holding AMRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($22.71)
- NEUTRAL: PE elevated vs history but 7.5% growth expectation is conservative given 157% recent growth
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$17.23 -
$19.63
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$18.74
Resistance Level
$21.18
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.83
Wall Street Target
$22.71
(+13.2%)
Revenue Growth (YoY)
9.9%
Earnings Growth (YoY)
157.1%
Profit Margin
5.1%
Valuation Premium vs History
+7.5% premium
PE vs Historical
16.8 vs 13.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.5%
(market-implied from PE analysis)
1-Year Target
$21.58
(+8%)
2-Year Target
$23.19
(+16%)
3-Year Target
$24.93
(+24%)
3-Yr Target (if PE normalizes)
(PE: 17→14)
PE COMPRESSION
$20.00
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 16.5%)
$38.42
(+91%)
Base:
(SPY PE: 16.8, Growth: 16.5%)
$31.70
(+58%)
Bear:
(PE: 13.5, Growth: 16.5%)
$25.43
(+27%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (42x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 41.96 | Current EPS (TTM): $0.48
Bull Case
$44.31
(+121%)
Analyst growth 100.0%, PE expands to 46.2
Base Case
$40.28
(+101%)
Market implied 100.0%, PE stable at 42.0
Bear Case
$13.70
(-32%)
Severe decline -20.0%, PE contracts to 35.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 2:16 PM ET
Data refreshes hourly during market hours. Next update: 3:16 PM
Data refreshes hourly during market hours. Next update: 3:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
Advanced AMRX Option Strategies
Professional options setups generated by AI based on today's AMRX price and gamma walls.
